ATE353639T1 - In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb - Google Patents
In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kbInfo
- Publication number
- ATE353639T1 ATE353639T1 AT01916022T AT01916022T ATE353639T1 AT E353639 T1 ATE353639 T1 AT E353639T1 AT 01916022 T AT01916022 T AT 01916022T AT 01916022 T AT01916022 T AT 01916022T AT E353639 T1 ATE353639 T1 AT E353639T1
- Authority
- AT
- Austria
- Prior art keywords
- astaxanthin
- man
- animal
- inhibit
- activation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0001071A SE0001071D0 (sv) | 2000-03-27 | 2000-03-27 | Method of inhibiting the expression of inflammatory cytokines and chemokines |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE353639T1 true ATE353639T1 (de) | 2007-03-15 |
Family
ID=20279020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01916022T ATE353639T1 (de) | 2000-03-27 | 2001-03-21 | In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1267857B1 (de) |
JP (1) | JP2003528139A (de) |
AT (1) | ATE353639T1 (de) |
AU (1) | AU2001242965A1 (de) |
CA (1) | CA2405479C (de) |
DE (1) | DE60126591D1 (de) |
SE (1) | SE0001071D0 (de) |
WO (1) | WO2001072296A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002349784A1 (en) * | 2001-12-03 | 2003-06-17 | Asahi Kasei Pharma Corporation | Nf-kappab activating genes |
JPWO2005074907A1 (ja) * | 2004-02-04 | 2007-09-13 | 富士化学工業株式会社 | 遺伝子発現調節剤 |
JP2006008714A (ja) * | 2005-03-17 | 2006-01-12 | Yamaha Motor Co Ltd | マトリックスメタロプロテイナーゼ阻害剤 |
JP2006008718A (ja) * | 2005-06-03 | 2006-01-12 | Yamaha Motor Co Ltd | シクロオキシゲナーゼ活性阻害剤 |
JP2006008719A (ja) * | 2005-06-23 | 2006-01-12 | Yamaha Motor Co Ltd | 血中過酸化脂質抑制剤 |
WO2008106606A2 (en) * | 2007-02-28 | 2008-09-04 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs and derivatives in the treatment of prostate cancer |
US7805004B2 (en) * | 2007-02-28 | 2010-09-28 | Microsoft Corporation | Radical set determination for HMM based east asian character recognition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05155736A (ja) * | 1991-12-10 | 1993-06-22 | Nakano Seiyaku Kk | 化粧料 |
JPH0799924A (ja) * | 1993-09-30 | 1995-04-18 | Nippon Suisan Kaisha Ltd | アスタキサンチンを主要成分とするファフィア色素油の安定な粉末化物及びその製造方法 |
JPH07300421A (ja) * | 1994-04-28 | 1995-11-14 | Itano Reitou Kk | 抗炎症剤 |
US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
AU4715796A (en) * | 1995-02-03 | 1996-08-21 | Basf Aktiengesellschaft | Use of carotinoids for preparing medicaments for treating dermatoses |
JPH09124470A (ja) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
JPH09143063A (ja) * | 1995-11-22 | 1997-06-03 | Kose Corp | 外用に適する組成物 |
SE522246C2 (sv) * | 1997-02-27 | 2004-01-27 | Astacarotene Ab | Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion |
EP0984915A4 (de) * | 1997-04-04 | 2002-11-27 | Henkel Corp | Luteinester mit hoher bioverfügbarkeit |
SE512531C2 (sv) * | 1997-09-04 | 2000-03-27 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur |
-
2000
- 2000-03-27 SE SE0001071A patent/SE0001071D0/xx unknown
-
2001
- 2001-03-21 CA CA2405479A patent/CA2405479C/en not_active Expired - Fee Related
- 2001-03-21 EP EP01916022A patent/EP1267857B1/de not_active Expired - Lifetime
- 2001-03-21 AU AU2001242965A patent/AU2001242965A1/en not_active Abandoned
- 2001-03-21 DE DE60126591T patent/DE60126591D1/de not_active Expired - Fee Related
- 2001-03-21 AT AT01916022T patent/ATE353639T1/de not_active IP Right Cessation
- 2001-03-21 WO PCT/SE2001/000600 patent/WO2001072296A1/en active IP Right Grant
- 2001-03-21 JP JP2001570257A patent/JP2003528139A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2003528139A (ja) | 2003-09-24 |
SE0001071D0 (sv) | 2000-03-27 |
AU2001242965A1 (en) | 2001-10-08 |
DE60126591D1 (de) | 2007-03-29 |
EP1267857B1 (de) | 2007-02-14 |
CA2405479C (en) | 2010-11-16 |
CA2405479A1 (en) | 2001-10-04 |
WO2001072296A1 (en) | 2001-10-04 |
EP1267857A1 (de) | 2003-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR003463A1 (es) | Una formulacion de liberacion controlada o de liberacion retardada; su utilizacion en la fabricacion de un medicamento y un procedimiento para su preparacion. | |
ATE269089T1 (de) | Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen | |
AR025247A1 (es) | Composiciones de granulos de carotenos-xantofilos, estables | |
MY111791A (en) | Aqueous gel retinoid dosage form. | |
BR9406363A (pt) | Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico | |
ES2194501T3 (es) | Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen. | |
SV2004001556A (es) | Preparaciones acidas de insulina con establidad mejorada | |
TR200100610T2 (tr) | Asetil L-karnitin ve alfa-lipoik asit içeren antioksidant bileşim | |
CY1106541T1 (el) | Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης | |
SE9704870D0 (sv) | New pharmaceutical formulation I | |
DK0650483T3 (da) | (3R,4R)-Delta6-tetrahydrocannabinol-7-syrer | |
ES2185155T3 (es) | Agentes conservantes de madera para la proteccion subsiguiente. | |
CO5580776A2 (es) | Formulacion farmaceutica estable en solucion de oxaliplatino | |
BR0311460A (pt) | Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente | |
BR9610480A (pt) | Inibição do fator alfa de necrose tumoral | |
DE60108489D1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
DK1167354T3 (da) | Racemisk huperzin A | |
AR003176A1 (es) | Una composicion farmaceutica para inhibir el crecimiento de cancer | |
ES2032955T3 (es) | Sal sodica anhidra cristalina de 5-cloro-3-(2-tenoil)-2-oxindol-1-carboxamida. | |
CO5011082A1 (es) | Formulacion medicamentosa con liberacion controlada de sus- tancia activa | |
ATE353639T1 (de) | In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb | |
AR023699A1 (es) | Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica | |
ATE444739T1 (de) | Polymerzusammensetzung sowie diese enthaltende darreichungsformen | |
ES2176702T3 (es) | Antimicoticos con alta liberacion de sustancia activa. | |
GEP20043231B (en) | Resorcinol Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |